Amount of damages awarded to the plaintiff in the legal matter.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

Name:	us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Litigation (European Commission Proceedings) (Narrative) (Details) € in Millions, $ in Millions		1 Months Ended	3 Months Ended
	Jul. 09, 2014 EUR (€)	Jun. 19, 2013 EUR (€)	Mar. 31, 2015 USD ($)	Jun. 30, 2020 USD ($)
European Commission Proceedings - Perindorpril \| Antitrust Proceedings \| Mylan Laboratories Limited
Loss Contingencies [Line Items]
Damages to be paid	€ 17.2
European Commission Proceedings - Perindorpril \| Antitrust Proceedings \| Mylan
Loss Contingencies [Line Items]
Damages to be paid	€ 8.0		$ 21.7
European Union Commission Proceedings - Citalopram
Loss Contingencies [Line Items]
Damages awarded		€ 7.8
Loss Contingency Accrual \| $				$ 7.4